Financing Snapshot: The company announced a $100m series B round that it plans to use to develop its regulatory RNA platform technology, with an eye toward entering the clinic in mid-2023.
Who: CAMP4 Therapeutics
Funding Round: $100m series B,
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.
The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.
